NUCLIDIUM AG
PrivateLast Round
Series B
Extension
May 27, 2026
Total Funding Raised
$162.63M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
NUCLIDIUM AG is a biotechnology company developing next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Imaging, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NUCLIDIUM AG Comparables
Compare NUCLIDIUM AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ratio Therapeutics Inc. | 84% | |
| Alpha-9 Oncology | 83% | |
| Clarity Pharmaceuticals | 80% |
NUCLIDIUM AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 27, 2026 | ||||
| Series B | Jul 10, 2025 | ||||
| Grant | Jun 27, 2022 | ||||
| Grant | Jan 27, 2022 | ||||
| Series A | Jun 23, 2021 | ||||
Grant | Sep 21, 2020 |
Key People
Founding team and executive leadership
NUCLIDIUM AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series B |
| European Innovation Council Fund | Grant |
| Highlight Capital | Series B |
| Neva SGR | Series B, Series B Extension |
| DeepTech & Climate Fonds | Series B, Series B Extension |
| European Investment Bank Group | Series B |
| VIVES Partners | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 24, 2026
Grew 29% QoQ, from 31 to 40 employees.
- Aug 21, 2026
Monthly visitors increased 65% MoM, reaching 3.1K.
NUCLIDIUM AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NUCLIDIUM AG's valuation, stock price, and market status.
Is NUCLIDIUM AG a public or private company?
NUCLIDIUM AG is a private company.
What is the current stock price of NUCLIDIUM AG?
NUCLIDIUM AG is a private company, so its shares have no public market price. Caplight tracks NUCLIDIUM AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NUCLIDIUM AG worth (valuation)?
Valuation information for NUCLIDIUM AG is not publicly available.
Can I buy NUCLIDIUM AG stock?
NUCLIDIUM AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NUCLIDIUM AG's last funding round?
NUCLIDIUM AG's most recent funding round was Series B Extension on May 27, 2026.
Who are the main investors in NUCLIDIUM AG?
Key investors in NUCLIDIUM AG include Neva SGR, Angelini Ventures, Wellington Partners, Kurma Partners.
Will NUCLIDIUM AG IPO soon?
No public IPO plans have been announced for NUCLIDIUM AG.
How can I track NUCLIDIUM AG secondary market activity?
Caplight tracks bids, offers, and trades in NUCLIDIUM AG's shares on secondary markets.